The diagnosis and treatment of the ADHD and selective mutism in a female adolescent patient who was Fragile X full mutant will be discussed in this case report.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Fragile X Syndrome is a genetic disease defined by cognitive and behavioral characteristics that accompany apparent physical features.
📊
Key Findings & Data:Male individuals are affected by this syndrome more severely, and it is the most common cause of mental retardation in men.
💡
Conclusion & Impact:The diagnosis and treatment of the ADHD and selective mutism in a female adolescent patient who was Fragile X full mutant will be discussed in this case report.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Fragile X Syndrome is a genetic disease defined by cognitive and behavioral characteristics that accompany apparent physical features. Male individuals are affected by this syndrome more severely, and it is the most common cause of mental retardation in men. The most common accompanying psychiatric conditions are mental retardation, autism, Attention Deficit Hyperactivity Disorder (ADHD), anxiety disorder, depression, sleep disorders and aggression. Anxiety, depression, shyness and social withdrawal are more common in female individuals. The diagnosis and treatment of the ADHD and selective mutism in a female adolescent patient who was Fragile X full mutant will be discussed in this case report.
🔖
Cite This Article
OKYAR, E., BOZATLI, L., GÖRKER, I. (2019). Atomoxetine Treatment in a Patient with the Comorbidity of Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. Psychiatry and behavioral sciences (Online), Cilt: 9 - Sayı: 4, 195–197. https://ajindex.com/articles/302857
45(4):190-8. [CrossRef] 3. Lee AW, Ventola P, Budimirovic D, Berry-Kravis E, Visootsak J. Clinical development of targeted fragile X syndrome treatments: an industry perspective. Brain Sci 2018
8(12). 4. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers 2017
17065. [CrossRef] 5. Keysor CS, Mazzocco MM. A developmental approach to understanding fragile X syndrome in females. Microsc Res Tech 2002
57(3):179–86. [CrossRef] 6. Talisa VB, Boyle L, Crafa D, Kaufmann WE. Autism and anxiety in males with Fragile X syndrome: an exploratory analysis of neurobehavioral profiles from a parent survey. Am J Med Genet A 2014
164A(5):1198–203. [CrossRef] 7. Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics 1993
91(2):321-9. 8. Turk J. Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry 2011
24(5):387–97. [CrossRef] 9. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: A retrospective chart review. Autism Res Treat 2012
104317. [CrossRef] 10. Hagerman RJ, Polussa J. Treatment of the psychiatric problems associated with fragile X syndrome. Curr Opin Psychiatry 2015
28(2):107–12. [CrossRef] 11. Hagerman RJ, Hills J, Scharfenaker S, Lewis H. Fragile X syndrome and selective mutism. Am J Med Genet 1999
83(4):313-7. 12. Kora M, Alyanak B, Mukaddes NM. Methylphenidate treatment in two cases with fragile-X syndrome who exhibited. Bulletin of Clinical Psychopharmacology 1999
9(3):170-2. [Turkish] 13. Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol 2016
6(5):317-4. [CrossRef] 14. Snircova E, Marcincakova-Husarova V, Hrtanek I, Kulhan T, Ondrejkal I, Nosalova G. Anxiety reduction on atomoxetine and methylphenidate medication in children with